StockNews.AI
ORN
StockNews.AI
57 days

141,959 Orion Corporation A shares converted into B shares

1. 141,959 Orion A shares converted to B shares. 2. Total shares now 141,134,278 including 32M A and 108M B shares. 3. The share conversion affects voting rights with 755M total votes. 4. Orion's 2024 net sales reached EUR 1,542 million. 5. Company focuses on oncology, pain, and has a strong global presence.

3m saved
Insight
Article

FAQ

Why Neutral?

Share conversion is a routine corporate action with minimal immediate price effect.

How important is it?

Routine share conversion may maintain stability but lacks significant impact drivers.

Why Short Term?

The conversion is unlikely to affect fundamentals or trading sentiment soon.

Related Companies

N/A
June 23, 2025 02:30 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST         141,959 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 141,959 A shares have been converted into 141,959 B shares. The conversion has been entered into the Trade Register on 23 June 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,308,783 A shares and 108,825,495 B shares. The number of votes of the company's shares is after the conversion 755,001,155. Orion Corporation Liisa HurmePresident and CEO    Mikko KemppainenGeneral Counsel   Contact person:Tuukka Hirvonen, Head of Investor Relations, tel. +358 10 426 2721                                                  Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orionpharma.com Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.

Related News